Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a chest infection leave lasting effects on daily life?

NCT ID NCT07807917

Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study follows adults hospitalized with a lower respiratory tract infection, such as pneumonia or bronchitis, to measure how their quality of life changes over one year. Researchers use a standard questionnaire to track physical, mental, and social well-being at several points after discharge. They also calculate the financial costs patients face during recovery. The goal is to understand why some people recover slowly and to inform future efforts to improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could identify factors that slow recovery after a chest infection, guiding future efforts to improve quality of life and reduce patient costs.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may not apply to all patients, and quality-of-life measures rely on self-reporting, which can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from the adult respiratory wards at Nottingham City Hospital as the majority of patients with a primary diagnosis of lower respiratory tract infection are admitted to these wards.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18years (no upper age limit). * Treated by attending physician as lower respiratory tract infection/community-acquired pneumonia, regardless of microbiologically-confirmed pathogen. * Ability to give informed consent or appropriate consultee available to give advice. Exclusion Criteria: * Hospital admission within 14 days preceding the index admission * Post-obstructive pneumonia secondary to Lung Cancer * Patients treated for active Tuberculosis (TB) * Receiving palliative treatment only * Unable to understand written or spoken English * Presumed to be unable to answer the questionnaires over the follow-up period. * Exacerbations of chronic lung disease such as asthma, COPD or bronchiectasis. * Previously enrolled in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chest infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchitis lower respiratory tract disorder pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chest infection Lower respiratory tract infection (LRTI) Quality of life

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nottingham City Hospital

    Nottingham, NG5 1PB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.